Skip to main content

Advertisement

SpringerLink
Log in

Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Associations of thrombocytosis, neutrophilia, and lymphopenia with prognosis have been confirmed in many cancers. This study aims at comparing various prognostic indices based on blood counts in metastatic colorectal adenocarcinomas.

Patients and Methods

Records from 152 patients with metastatic colorectal cancer who were treated in our center were reviewed. Demographic and disease characteristics and hematologic parameters data were extracted and patients were stratified according to their scores of several hematologic ratios. Hematologic ratios and parameters considered included the platelet-neutrophil to lymphocyte ratio (PNLR), the platelet to lymphocyte ratio (PLR), the neutrophil to lymphocyte ratio (NLR), the Abnormal Hematological Markers Index (AHMI), and the neutrophil-platelet score (NPS). Optimal cutoffs were defined with the aid of an online tool. Baseline parameters of the two groups derived for each tool were evaluated and compared with the χ2 test. Univariate and multivariate Cox proportional-hazards regression analyses were performed on variables of interest.

Results

Progression-Free Survival (PFS) hazard ratios (HR) between the high-risk and low-risk groups derived from the multivariate analyses for each index were as follows: for PNLR 2.0 (95% CI 1.28–3.13), for PLR 1.74 (95% CI 1.13–2.67), for NLR 1.54 (95% CI 1.04–2.29), for AHMI 1.62 (95% CI 1.06–2.46), and for NPS 1.47 (95% CI 1.1–1.96). Overall Survival (OS) hazard ratios (HR) derived from the multivariate analyses for each index were as follows: for PNLR 2.23 (95% CI 1.36–3.66), for PLR 1.68 (95% CI 1.03–2.75), for NLR 1.62 (95% CI 1.06–2.49), for AHMI 1.7 (95% CI 1.07–2.69), and for NPS 1.53 (95% CI 1.11–2.11). Another prognostic index called PRONOPALL, which is based on ECOG PS (0–1 versus 2–3 versus 4), number of metastatic sites (≤ 1 versus ≥ 2), LDH (< 600 U/L versus ≥ 600 U/L), and albumin (≥ 33 g/L versus < 33 g/L), had HRs of 1.75 and 2.20 for PFS and OS, respectively, with a cutoff of < 4 versus ≥ 4. This score has a range of 0 to 10 and points are attributed for the presence of each of the four prognostic factors.

Conclusion

In this analysis of metastatic colorectal cancer patients, several ratios and other prognostic tools had prognostic value for both OS and PFS. While other variables held significance for poorer prognosis, PNLR had the highest HR and the highest significance in multivariate analysis for both PFS and OS. Thus, it represents a valid prognostic tool in metastatic colorectal cancer among the spectrum of hematologic parameter-constructed tools.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2015;25:16–27.

    Article  Google Scholar 

  2. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Voutsadakis IA. Immune blockade inhibition in breast cancer. Anticancer Res. 2016;36:5607–22.

    Article  CAS  PubMed  Google Scholar 

  4. Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative lymphocyte-to-monoocyte ratio in patients with colorectal cancer. Oncol Lett. 2017;13:1000–6.

    Article  CAS  PubMed  Google Scholar 

  5. Younes G, Segev Y, Begal J, Auslender R, Goldberg Y, Amit A, et al. The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC). Eur J Gynecol Reprod Biol. 2016;199:16–20.

    Article  Google Scholar 

  6. Su Z, Mao Y-P, Ou Yang P-Y, et al. Initial hyperleukocytosis and neutrophilia in nasopharyngeal carcinoma: incidence and prognostic impact. PLoS One. 2015;10:e0136752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–5.

    Article  CAS  PubMed  Google Scholar 

  8. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Voutsadakis IA. Thrombocytosis as a prognostic marker in gastrointestinal cancers. World J Gastrointest Oncol. 2014;6:34–40.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2013;134:2403–13.

    Article  CAS  Google Scholar 

  11. Tan D, Fu Y, Su Q, Wand H. Prognostic role of platelet–lymphocyte ratio in colorectal cancer—a systematic review and meta-analysis. Medicine. 2016;24(e3837):95.

    Google Scholar 

  12. Mercier J, Voutsadakis IA. The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. J Gastrointest Oncol. 2018; (in press)

  13. Bourgeois H, Grudé F, Solal-Céligny P, Dupuis O, Voog E, Ganem G, et al. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Ann Oncol. 2017;28:1612–7.

    Article  CAS  PubMed  Google Scholar 

  14. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, et al. Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2017;35:1929–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.

    Article  CAS  PubMed  Google Scholar 

  16. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6.

    Article  CAS  PubMed  Google Scholar 

  17. Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015:983698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Vogt Sionov R, Fridlender ZG, Granot Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 2015;8:125–58.

    Article  CAS  Google Scholar 

  19. Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol. 2014;41:174–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Liang L, Zhu J, Jia H, et al. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy. Oncotarget. 2015;7:1014–28.

    PubMed Central  Google Scholar 

  21. Stravodimou A, Voutsadakis IA. Pre-treatment thrombocytosis as a prognostic marker in metastatic breast cancer. Int J Breast Cancer. 2013;2013:289563.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kim M, Chang H, Yang HC, Kim Y, Lee CT, Lee JH, et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol. 2014;12:37.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Steele M, Voutsadakis IA. Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma. World J Gastrointest Oncol. 2017;9:42–9.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130:2747–60.

    Article  CAS  PubMed  Google Scholar 

  25. Ho-Tin-Noé B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol. 2009;175:1699–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69:7775–83.

    Article  CAS  PubMed  Google Scholar 

  28. Watt DG, Proctor MJ, Park JH, Horgan PG, McMillan DC. The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS One. 2015;10:e0142159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med. 2016;374:211–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was partly supported by a Dean’s summer student research award of the Northern Ontario School of Medicine, Canada.

Author information

Authors and Affiliations

  1. Northern Ontario School of Medicine, Division of Clinical Sciences, Sudbury, ON, Canada

    Joey Mercier & Ioannis A. Voutsadakis

  2. Algoma District Cancer Program, Sault Area Hospital, 750 Great Northern Road, Sault Ste. Marie, ON, P6B 0A8, Canada

    Ioannis A. Voutsadakis

Authors
  1. Joey Mercier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioannis A. Voutsadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis A. Voutsadakis.

Ethics declarations

Conflicts of Interests

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mercier, J., Voutsadakis, I.A. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer. J Gastrointest Canc 50, 493–506 (2019). https://doi.org/10.1007/s12029-018-0108-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-018-0108-1

Keywords

Search

Navigation